DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial - Ledgerwood, Julie E.; Bellamy, Abbie R.; Belshe, Robert; Bernstein, David I.; Edupuganti, Srilatha; Patel, Shital M.; Renehan, Phyllis; Zajdowicz, Thad; Schwartz, Richard; Koup, Richard; Bailer, Robert T.; Yamshchikov, Galina V.; et al. (PloS one, 2015)
Keywords: Adult; Adults; Aged; Antibody response; Antigens; At risk populations; Avian flu; Care and treatment; Clinical trials; Deoxyribonucleic acid; DNA; DNA vaccines; Double-Blind Method; Double-blind studies; FDA approval; Female; Hemagglutination; Hemagglutination inhibition; Hospitals; Humans; Immune response; Immunity; Immunogenicity; Infectious diseases; Influenza; Influenza A Virus, H5N1 Subtype - genetics; Influenza A Virus, H5N1 Subtype - immunology; Influenza vaccines; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - prevention & control; Injections, Intramuscular; Licenses; Male; Manufacturing; Medicine; Middle Aged; Optimization; Pandemics; Patient outcomes; Phosphates; Prevention; Priming; Production capacity; Risk factors; Seasons; Studies; Swine flu; Vaccines; Vaccines, DNA - administration & dosage; Vaccines, DNA - adverse effects; Vaccines, DNA - immunology; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - immunology; Young Adult; California